Statements (59)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:monoclonal_antibody
|
| gptkbp:bfsLayer |
4
|
| gptkbp:bfsParent |
gptkb:Praluent
|
| gptkbp:activities |
inhibits PCS K9 protein
|
| gptkbp:appointed_by |
subcutaneous injection
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:class |
PCS K9 inhibitor
|
| gptkbp:clinical_trial |
not applicable
Phase III as adjunct therapy reduced cardiovascular events significant LDL reduction |
| gptkbp:contraindication |
hypersensitivity to alirocumab
|
| gptkbp:developed_by |
gptkb:Sanofi
|
| gptkbp:dosage_form |
injection solution
|
| gptkbp:duration |
long-term therapy
|
| gptkbp:education |
important for understanding therapy
|
| gptkbp:effective_date |
gptkb:2015
|
| gptkbp:excretion |
via the reticuloendothelial system
|
| gptkbp:financial_performance |
stable until expiration date
|
| gptkbp:formulation |
available in 75 mg and 150 mg
|
| gptkbp:frequency |
once every two weeks
|
| gptkbp:healthcare |
necessary for proper administration
|
| https://www.w3.org/2000/01/rdf-schema#label |
alirocumab
|
| gptkbp:indication |
hyperlipidemia
|
| gptkbp:ingredients |
C6424 H9920 N1716 O1984 S44
|
| gptkbp:interacts_with |
other lipid-lowering therapies
|
| gptkbp:invention |
2026
|
| gptkbp:is_effective_against |
improves patient outcomes
demonstrated in trials |
| gptkbp:is_monitored_by |
liver function tests
lipid levels signs of allergic reactions |
| gptkbp:is_used_for |
lowering LDL cholesterol
|
| gptkbp:lifespan |
approximately 17 to 20 days
|
| gptkbp:manager |
subcutaneous
|
| gptkbp:market |
gptkb:stock_market_index
|
| gptkbp:marketed_as |
gptkb:Praluent
|
| gptkbp:metabolism |
proteolytic degradation
|
| gptkbp:pharmacokinetics |
linear pharmacokinetics
reduces LDL levels |
| gptkbp:population |
adults with atherosclerotic cardiovascular disease
adults with familial hypercholesterolemia |
| gptkbp:price |
varies by region and insurance
|
| gptkbp:provides_information_on |
included in cholesterol management guidelines
|
| gptkbp:regulatory_compliance |
gptkb:Health_Canada
gptkb:European_Medicines_Agency |
| gptkbp:research_focus |
long-term safety
cardiovascular outcomes combinations with other therapies |
| gptkbp:scholarships |
gptkb:stock_market_index
|
| gptkbp:side_effect |
allergic reactions
recommended injection site reactions nasopharyngitis myalgia |
| gptkbp:storage |
refrigerated
|
| gptkbp:targets |
PCS K9
|
| gptkbp:type_of_care |
important for efficacy
|